Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role
September 21 2021 - 8:31AM
Business Wire
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage
biopharmaceutical company focused on discovering, acquiring,
developing and commercializing therapeutics in the disease areas of
immunology, inflammation and oncology, today announced that, Bryan
Giraudo has been appointed Chief Operating Officer, in addition to
his continued role as Chief Financial Officer. Mr. Giraudo joined
Gossamer in May 2018 as its Chief Financial Officer.
“Bryan has been instrumental in strengthening the financial and
organizational foundation of the Company,” said Faheem Hasnain,
Chairman, co-founder and CEO of Gossamer Bio. “Since his arrival at
Gossamer, his responsibilities have extended far beyond just the
finance and accounting groups, and this promotion reflects the
management and leadership role that Bryan has already established
for himself.”
Prior to joining Gossamer Bio, Mr. Giraudo was a Senior Managing
Director at Leerink Partners, now known as SVB Leerink, from 2009
to April 2018. Before joining Leerink, Mr. Giraudo was a Managing
Director in Merrill Lynch’s Global Healthcare Investment Banking
Group.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company
focused on discovering, acquiring, developing and commercializing
therapeutics in the disease areas of immunology, inflammation and
oncology. Its goal is to be an industry leader in each of these
therapeutic areas and to enhance and extend the lives of patients
suffering from such diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210921005468/en/
For Investors and Media: Bryan Giraudo, Chief Operating
Officer & Chief Financial Officer Gossamer Bio Investor
Relations ir@gossamerbio.com
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Apr 2023 to Apr 2024